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INTRODUCTION
Liver transplantation is the well-established, life-saving
therapeutic modality for children with end-stage liver dis-
ease. With recent advancements in surgical techniques and
immunosuppressive drugs, survival after liver transplantation
has improved remarkably since the introduction of clinical
transplantation by Starzl et al. 40 yr ago (1-5). Liver cirrhosis
in children differs from that in adults because it is frequently
accompanied by growth failure (6). Therefore evaluating a
child’s growth following liver transplantation is used to mea-
sure quality of life.
It is well established that liver transplantation results not
only in long-term survival, but also in normal growth and
development (7-12). However, most of these studies involved
cadaveric donor liver transplantation. Therefore we performed
this study in order to evaluate the long-term effect of living
donor liver transplantation (LDLT) on child growth. We also
assessed the influence of other factors on post-LDLT child
growth such as the primary diagnosis, pre-transplantation
growth retardation, liver graft function following transplan-
tation, and immunosuppressive regimen.
MATERIALS AND METHODS
From a total of 43 children who had undergone LDLT at
the Asan Medical Center from 1994 to 1999, 36 children
(84%) who had survived over 5 yr were enrolled in this study.
Profiles of these children are listed in Table 1. Median age
at transplantation was 1.5 yr (range: 6 months-15 yr) and
the median follow-up period was 6.5 yr (range: 5-9 yr). Twen-
ty-three of the 36 children underwent LDLT for biliary atresia,
5 for Wilson disease, 3 for fulminant hepatitis of unknown
etiology, 2 for unexplained liver cirrhosis, 1 for intrahepatic
bile duct paucity, 1 for Byler disease, and 1 for ornithine tran-
scarbamylase deficiency. Seven of the 36 children had fulmi-
nant hepatitis. As for the immunosuppressive regimen, 11
children were initially treated with cyclosporin A (CyA) and
a low dose corticosteroid while the other 25 children were
treated with FK 506.
Follow-up evaluations occurred in 6-month-intervals on an
outpatient basis, except during the 1st yr post-LDLT, when
check-ups were more frequent. Medical records of pre-trans-
plant and post-transplant examinations were reviewed retro-
spectively.
For statistical evaluation, a repeated measures ANOVA was
used. Data regarding height were expressed as mean height
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Long-term Growth of Pediatric Patients Following Living-Donor Liver
Transplantation
In order to determine the influence of living donor liver transplantation (LDLT) on
long-term growth, we studied the progress of 36 children who had survived more
than 5 yr after LDLT from 1994 to 1999. The median age at the transplantation was
1.5 yr (range: 6 months-15 yr) and the median follow-up period was 6.5 yr (range:
5-9 yr). A height standard deviation score (zH) was analyzed for each patient accord-
ing to medical records. Significant catch-up growth occurred within 2 yr after LDLT
with a mean zH changing from -1.2 to 0.0 and was maintained for up to 7 yr post-trans-
plantation (zH-0.1). Younger children (<2 yr) were more growth-retarded at the time
of LDLT, but showed higher catch-up growth rates and their final zH was greater
than that of older children. Children with liver cirrhosis were more growth-retarded
at the time of LDLT, but showed significant catch-up growth and their final height
was similar to children with fulminant hepatitis. Growth in children who experienced
significant hepatic dysfunction after LDLT was not significantly different from those
without graft dysfunction. There was no difference between the types of immuno-
suppressants used. Our finding suggests that LDLT can result in adequate catch-
up linear growth, and this effect can persist even after 7 yr post-transplantation.
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standard deviation scores (zH). zH was calculated according
to the equation: zH=(X-mean height)/standard deviation,
where X represents the actual measured height in centime-
ters and the mean height and standard deviation (SD) repre-
sent values of an age- and gender-matched mean height curve
from the Korean Pediatric Society Reference published in
1997. Normal growth was defined as zH over -1.5 at the time
of LDLT and having the same zH afterwards, essentially stay-
ing on the same percentile line for height. Retarded growth
at the time of transplantation was defined as zH under -1.5
for the patient’s age. Catch-up growth was defined as a gain
in zH after LDLT, i.e., crossing the percentile lines for height
(13). Lack of growth was defined as a decrease in zH after
LDLT.
In order to get an impression of overall growth, we plotted
the mean zH versus the number of months post-LDLT for all
36 patients. We then created a homogenous group by select-
ing 29 of the 36 children who were younger than 6-yr-old
at the time of transplantation which eliminated the variation
due to pubertal growth spurt. We then examined the influ-
ence of pre-transplant growth retardation, primary diagnosis
of fulminant hepatitis or chronic cirrhosis, post-transplanta-
tion liver graft function, and immunosuppressive regimen.
RESULTS
Post-LDLT linear growth of all children 
Progression of zH, post-LDLT, of all 36 children is shown
in Fig. 1. zH values (mean±SD) at the time of LDLT, and
2 and 7 yr after LDLT were -1.2±1.2, 0.0±0.9 and -0.1±
1.1, respectively, indicating that there was significant catch-
up growth for the first 2 yr and a maintenance of continuous
growth in height for up to 7 yr (p<0.01).
Post-LDLT linear growth of children under 6 yr of age 
A more precise impression of growth post-LDLT is provided
in Fig. 2, in which the mean zH is plotted against months
post-LDLT for each of the 29 children who were younger
than 6 yr at the time of transplantation. By only including
children younger than 6 yr, we removed the compounding
effect of pubertal growth spurt. zH values at the time of LDLT,
and 2 and 7 yr after LDLT were -1.5±1.0, 0.0±0.8 and
-0.3±1.1, indicating a similar pattern as was observed for
the entire group (p<0.01). 
Post-LDLT linear growth of patients exhibiting growth
retardation at the time of transplantation
zH values (mean±SD) for the 15 children with retarded
growth at the time of LDLT, and 2 and 7 yr after LDLT were
-2.3±0.6, -0.4±0.8 and -0.8±0.8 respectively, suggesting
zH runs to the zero baseline 2 yr after LDLT. It also implies
that there was significant catch-up growth within 2 yr after
LDLT (p<0.01) and the maintenance of continuous growth
after catch-up growth in height for up to 7 yr. Furthermore,
the zH values for the 21 children with normal growth at the
time of LDLT, and 2 and 7 yr after LDLT were -0.4±0.9,
0.4±0.9 and 0.4±1.1, respectively, indicating that there Values are number (%).
Age 1.5 yr (range: 7 months -15 yr)
Recipient gender
Male 10 (28)
Female 26 (72)
Diagnosis of 36 recipients 
Biliary atresia 23 (64)
Wilson disease 5 (14)
Fulminant hepatitis 3 (8) 
Cryptogenic liver cirrhosis 2 (5)
Intrahepatic bile duct paucity 1 (3)
Byler disease 1 (3)
Ornithine transcarbamylase deficiency 1 (3)
Initial immunosuppression 
Cyclosporine, prednisolone 11 (31)
FK 506 25 (69)
Table 1. Patient demographics (n=36)
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Fig. 1. Post-transplantation mean height standard deviation scores
(zH) of all children in the study.
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Fig. 2. Post-transplantation mean height standard deviation scores
(zH) of children under 6 yr of age at the time of transplantation.Long-term Growth Following Living Donor Liver Transplantation 837
is no stunting of growth after LDLT. The growth gap between
the two groups was decreased at 2 and 7 yr post-LDLT from
the time of LDLT, but still persisted, indicating that children
with retarded growth improve after LDLT, but remain shorter
than those with normal growth (Fig. 3).
Post-LDLT linear growth in children with retarded growth
according to age
Eleven of the 15 children with retarded growth at the time
of LDLT were younger than 2 yr and the remaining 4 were
older. zH values (mean±SD) at the time of LDLT, and 2 yr
and 5 yr after LDLT were -2.4±0.6, -0.1±0.5 and -0.4±0.7
for the younger group (<2 yr old) and -2.1±0.5, -1.3±1.1
and -1.9±0.9 for older group, respectively. The younger group
showed more retarded growth at the time of LDLT, but showed
significantly higher catch-up growth after LDLT (p<0.05)
(Fig. 4). 
Post-LDLT linear growth according to underlying disease
at the time of LDLT
The mean zH for children with liver cirrhosis was signifi-
cantly different from those with fulminant hepatitis at the
time of LDLT. The zH (mean±SD) for the 31 children with
liver cirrhosis was -1.4±1.2, and -0.1±1.2 for the 5 chil-
dren with fulminant hepatitis. At 2 yr after LDLT, the mean
zH for children with liver cirrhosis was 0.0±1.0, and 0.5±
0.5 for those with fulminant hepatitis. After the 2-year fol-
low-up there was no statistical difference between the two
groups (p>0.05). This implies that children diagnosed with
liver cirrhosis experienced catch-up growth after LDLT, while
those with fulminant hepatitis showed maintenance of nor-
mal growth after LDLT (Fig. 5).
Post-LDLT linear growth in patients experiencing chronic
disease after liver transplantation
Seven of the 36 children experienced chronic diseases after
LDLT such as chronic rejection or post-transplant lympho-
proliferative disorder. There was no significant difference in
the preoperative, 2 and 7 yr post-LDLT mean zH values bet-
ween children who did and did not experience a chronic dis-
ease (p>0.05) (Fig. 6).
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Fig. 3. Post-transplantation mean height standard deviation scores
(zH) of children with retarded (    ) and normal growth (    ).
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Fig. 4. Post-transplantation mean height standard deviation scores
(zH) of children with retarded growth in the younger (<2 yr) (    )
and older age (    ) groups.
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Fig. 5. Post-transplantation mean height standard deviation scores
(zH) of children with fulminant hepatitis (    ) and liver cirrhosis (    ).
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Fig. 6. Post-transplantation mean height standard deviation scores
(zH) of children with episodes of chronic graft dysfunction (    ) and
normal hepatic function (    ).838 S.J. Park, S.-H. Rim, K.M. Kim, et al.
Post-LDLT linear growth according to the type of immuno-
suppression
Eleven children received cyclosporin A and a long-term
low dose corticosteroid (CyA group) and the remaining 25
children received FK506 with a short-term corticosteroid
(FK506 group). The mean height zH scores for the CyA group
at preoperative, 2 and 7 yr after LDLT were -0.8±1.6, 0.4
±1.0 and 0.0±1.3, respectively, and for the FK506 group
they were -1.4±1.0, -0.1±0.9 and -0.3±1.0. This result
indicates that there was no significant difference in linear
growth based on the type of immunosuppression (p>0.05)
(Fig. 7).
DISCUSSION
The purposes of this study were to investigate post-trans-
plantation linear growth in pediatric LDLT recipients and
to examine several variables that may affect their linear growth
after transplantation. In comparison to cadaveric donor liver
transplantation (CDLT), LDLT has several advantages: it is
usually performed electively, it requires a shorter waiting
time, the operating environment is superior, and the patient’s
condition can be controlled better (14-16). Therefore it is
hypothesized that LDLT will result in improved linear growth,
but only a few studies have investigated its influence (11-17).
We could not compare the linear growth between LDLT
and CDLT patients because only two children received CDLT
in our center during the study period. The scarcity of cadav-
eric donors is the largest obstacle for solid organ transplan-
tation in Korea, so LDLT has been vigorously adopted for
children since 1994 (5, 18) and expanded to adult patients
as well (4).
In our study, children after LDLT improved from a mean
zH score of -1.2 at the time of transplantation to -0.1 seven
years later. The patients in our study grew to almost normal
heights in comparison with their age and sex-matched peers.
Contrary to our results, McDiarmid et al. (7) demonstrated
in their recent study that even though orthotopic liver trans-
plantation showed some potential for catch-up growth, pati-
ents did not achieve normal height (from -1.7 to -1.4). The
difference in our findings can be explained by a higher pro-
portion of patients younger than 2 yr in our study (61 vs.
43%) at the time of transplantation. Younger children have
shown better achievement of growth in several studies (7, 8,
17). Our findings can be further explained by the advantages
of LDLT. The main advantage is its shorter waiting time,
which can reverse the effect of chronic liver disease and restore
the growth potential of young children. Our children also had
a higher zH score (-1.19 vs. -1.72) at the time of transplan-
tation, which can explain the LDLT in a better nutritional
status. In a short-term study by Renz et al. (17), they report-
ed that LDLT recipients had better mean zH at the time of
transplantation as well as 1 yr after transplantation.
Factors that may affect growth after transplantation can
be classified into pre-transplantation and post-transplanta-
tion factors. Known pre-transplantation factors are nutrition-
al status, growth retardation (10, 19, 20), age at transplan-
tation (7, 17), and underlying disease (17, 21). Known post-
transplantation factors are nutrition, intercurrent illness, im-
pairment of liver function (20, 22), and immunosuppression
(23).
As for pre-transplant growth retardation, our study showed
that children with pre-transplant growth retardation had
higher growth rates than those with normal growth. How-
ever, those patients still had shorter heights 7 yr after trans-
plantation. This suggests that children with initial growth
retardation have greater catch-up growth (high growth veloc-
ity) but the final height correlates with pre-transplant height
for the same age group. When these findings were reevalu-
ated according to age, our study showed that catch-up growth
was more prominent in patients less than 2 yr old, which has
been suggested in several other studies (7, 8, 17). This result
suggests that LDLT can be considered for children at young
ages who have chronic liver cirrhosis without definite indica-
tion for transplantation, but have growth retardation.
Our findings on the influence of primary diagnosis on post-
LDLT growth revealed that there was a remarkable difference
in the level of the plotted mean zH curves in favor of the
group with fulminant hepatitis. Apparently, there was stunt-
ed growth at the time of transplantation in children with
chronic liver cirrhosis (19) in contrast to children with fulmi-
nant hepatitis. An explanation for this difference is the earlier
onset of chronic liver cirrhosis and the often more complicat-
ed course due to recurrent cholangitis. In contrast, children
with fulminant hepatic failure often have good liver function
with normal growth before the onset of disease.
Comparing the influence of liver graft function on height
shows that poor graft function did not have a negative influ-
ence on post-transplantation growth in this long-term follow-
up study. This is interesting because our earlier study (24)
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Fig. 7. Post-transplantation mean height standard deviation scores
(zH) of children with prednisolone and cyclosporin (    ) or FK 506
(    ).and other studies (19-21, 25) have shown that poor graft func-
tion has a negative influence on post-transplantation growth.
In this study, we excluded children who died within 5 yr
after liver transplantation. Therefore most of the children in
our study did not have persistent poor graft function. This
result suggests that even if children have occasional poor graft
function, unless it is persistent, it will not affect height at
long-term follow-up.
Our results show there is no difference in growth between
the CyA and FK506 groups. Contrary to our results, several
earlier reports identified immunosuppression, in particular,
the use of steroids, as an additional variable that affects growth
after liver transplantation (8, 19, 26). However, each of these
previous reports used daily prednisone dosing of at least 5
mg/kg/day. We believe our lower pulse steroid regimen of 2
mg/kg/day with a rapid taper goal of 0.3 mg/kg/day by 1 week
post-transplantation and adopting an alternative day regimen
as soon as possible, even in children taking CyA, spared our
transplant recipients of the negative effects of steroids on linear
growth. This effect had been reported in recent studies (7,
10, 17) similar to ours, whereas an older study by Bartosh
et al. (8) showed a long-term negative impact of steroids on
post-transplantation growth.
Although this was not a comparative study including cadav-
eric liver transplantation, this study showed that LDLT restored
the growth in children with growth retardation by catch-up
growth, and preserve adequate growth in non-growth-retard-
ed children for up to 7 yr. Therefore LDLT appears to be a
promising modality not only in long term survival, but also
in long-term normal linear growth.
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